Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2309-2315

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patrono, C.
Right arrow Articles by FitzGerald, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patrono, C.
Right arrow Articles by FitzGerald, G. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*PROSTAGLANDIN F2ALPHA
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2309-2315.)
© 1997 American Heart Association, Inc.

Articles

Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease

Carlo Patrono; ; Garret A. FitzGerald

From the Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia.

Correspondence to Dr G.A. FitzGerald, Center for Experimental Therapeutics, University of Pennsylvania, 905 Stellar-Chance Laboratories, 422 Curie Blvd, Philadelphia, PA 19104-6100. E-mail garret{at}spirit.gcrc.upenn.edu


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMechanisms of Formation
 down arrowBiological Effects on Platelets...
 down arrowAnalytical Methods
 down arrowF2 Isoprostane...
 down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
Abstract Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF2{alpha} has been described in association with cardiac reperfusion injury and with cardiovascular risk factors, including cigarette smoking, diabetes mellitus, and hypercholesterolemia. Besides providing a likely noninvasive index of lipid peroxidation in these settings, measurements of specific F2 isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF2{alpha} in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation, evidence that this is likely in vivo remains inadequate at this time.


Key Words: F2 isoprostanes • lipid peroxidation • ischemia/reperfusion • hypercholesterolemia • cigarette smoking


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMechanisms of Formation
 down arrowBiological Effects on Platelets...
 down arrowAnalytical Methods
 down arrowF2 Isoprostane...
 down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
It is thought that the atherosclerotic lesion may develop as a specialized form of inflammatory response to oxidized phospholipids within the artery wall. The opposing determinants of lipid oxidation in the development of the fatty streak have been reviewed recently in this journal.1 Although a role for oxidative modification of specific phospholipids in human atherogenesis remains to be established, the in vitro properties of oxidized LDL are consistent with its importance in monocyte/macrophage recruitment. Exposure of trapped lipoproteins to the oxidative waste products of various cellular components of the arterial wall, as well as modulation of these phenomena by the antioxidants present on the LDL particles and in the surrounding microenvironment, are thought to be among the important determinants of atherogenesis.1 It is beyond the scope of this review to discuss the variety of biologically active lipids that result from LDL oxidation.1 2 3 Rather, we intend to focus on a new family of prostaglandin (PG) isomers (isoprostanes) that result from oxidative modification of arachidonic acid through a free radical–catalyzed mechanism.4 5 Formation of these compounds in vivo can be reliably monitored through noninvasive analytical approaches that yield sensitive and specific signals of lipid peroxidation. Moreover, the biological effects of isoprostanes might operate as transduction mechanisms linking oxidant stress to specialized forms of cellular activation, such as platelet activation and smooth muscle cell proliferation in human vascular disease.


*    Mechanisms of Formation
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Mechanisms of Formation
down arrowBiological Effects on Platelets...
 down arrowAnalytical Methods
 down arrowF2 Isoprostane...
 down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
F2 isoprostanes are a family of PGF2{alpha} isomers (Fig 1Down) first described as products of noncyclooxygenase oxidative modifications of arachidonic acid that have resulted from free-radical attack of cell membrane phospholipids5 or circulating LDLs.6 In contrast to classic PGs, which are formed through the action of PGH synthase isozymes from free arachidonic acid,7 F2 isoprostanes are formed in situ from the fatty acid backbone esterified in membrane phospholipids. They are released in response to cellular activation, presumably through a phospholipase-mediated mechanism; they circulate in plasma and are excreted in the urine.8 9 They may circulate as the free form or as esters in phospholipids in plasma. The factors that regulate release of endogenous isoprostanes from cell membranes and interconversion between the free and esterified forms are presently poorly understood.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1. Four classes of F2 isoprostanes that may be formed by free-radical attack on arachidonic acid. 8-iso-PGF2{alpha} may also be formed in a COX-dependent manner. PG indicates prostaglandin; COX, cyclooxygenase; and FR, free radical.

Given the ubiquitous distribution of the precursor arachidonic acid, isoprostane biosynthesis can occur in virtually all of the cellular players of the atherosclerotic lesion, including monocytes.10 Indeed, coincubation of activated human monocytes with LDL resulted in a time-dependent formation of the F2 isoprostane 8-iso-PGF2{alpha} but not of PGE2 or thromboxane (TX) B2, coincident with LDL oxidation.10 The increase in 8-iso-PGF2{alpha} formation was associated with an increase in thiobarbituric acid–reactive substance (TBARS) and hydroperoxide levels. This phenomenon was prevented by the oxygen free-radical scavengers SOD and BHT but not by cyclooxygenase inhibitors.10 Consistent with these in vitro studies, immunolocalization of 8-iso-PGF2{alpha} in the monocytes/macrophages and vascular smooth muscle cells of human atherosclerotic tissue has recently been described in specimens obtained during carotid endarterectomy.11

In addition to a cyclooxygenase-independent mechanism of formation involving peroxidative attack on arachidonic acid, in which bicyclic endoperoxide intermediates are formed that are then reduced to give rise to isoprostanes such as 8-iso-PGF2{alpha}, there is recent evidence that 8-iso-PGF2{alpha}, unlike other F2 isoprostanes, can be produced as a minor product of the cyclooxygenase activity of platelet PGH synthase-1 in response to platelet stimulation with collagen, thrombin, or arachidonate (Fig 1Up).9 12 Activated platelets can generate 8-iso-PGF2{alpha} and TXB2 in a molar ratio of {approx}1:1000.9 12 A second enzyme endowed with cyclooxygenase activity, PGH synthase-2, can be expressed in different cell types in response to inflammatory and mitogenic stimuli (reviewed in Reference 77 ). Induction of PGH synthase-2 in human monocytes by concanavalin A, phorbol ester, or bacterial lipopolysaccharide was associated with cyclooxygenase-dependent formation of 8-iso-PGF2{alpha} and PGE2 in a molar ratio ranging from 1:5 to 1:30.10 13 Dexamethasone, an inhibitor of PGH synthase-2 induction, and L-745337, a selective inhibitor of the cyclooxygenase activity of monocyte PGH synthase-2,14 dose-dependently suppressed 8-iso-PGF2{alpha} and PGE2 formation with similar potency.10 13

Although the contribution of cyclooxygenase-dependent mechanisms to the formation of 8-iso-PGF2{alpha} in vivo appears to be negligible under physiological circumstances,9 the general assumption that measurements of this F2 isoprostane in plasma or urine are a reflection of nonenzymatic lipid peroxidation requires validation in clinical settings of platelet and/or monocyte activation (see below).


*    Biological Effects on Platelets and Vascular Cells
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 *Biological Effects on Platelets...
down arrowAnalytical Methods
 down arrowF2 Isoprostane...
 down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
The formation of isoprostanes in lipid bilayers by a free radical–catalyzed mechanism may contribute importantly to alterations in the fluidity and integrity of cellular membranes. In addition, 8-iso-PGF2{alpha} is a potent vasoconstrictor15 and induces DNA synthesis in vascular smooth muscle cells, perhaps through interaction with receptors that are distinct from but closely related to PGH2/TXA2 receptors.16 Although a functional role for isoprostanes in atherogenesis remains to be established, discriminant production of this isoprostane by both reactive oxygen species and monocyte PGH synthase 2 within atherosclerotic plaques renders it a candidate molecule to transduce, at least in part, the effects of lipid peroxidation and inflammation on vascular dysfunction. Formation of isoprostanes in situ in the phospholipid bilayer may modify cell function. Subsequent cleavage may release products, such as 8-iso PGF2{alpha}, that modify aspects of platelet function such as adhesive reactions and activation by low concentrations of other agonists. Formation of isoprostanes in monocytes may modify aspects of their function, such as expression of tissue factor. Similarly, formation of isoprostanes in oxidized LDL may result in their uptake by monocytes/macrophages, resulting in the formation of foam cells. Isoprostanes may also modify vascular smooth muscle cell function and accumulate in these cells in proximity to atherosclerotic plaques (Fig 2Down).



View larger version (34K):
[in this window]
[in a new window]
  		Figure 2. Potential sites of isoprostane formation and cellular targets of 8-iso-PGF2{alpha} of relevance to atherothrombosis. ELAM indicates endothelial leukocyte adhesion molecule; PGI2, prostacyclin; PAF, platelet-activating factor; TX, throm- boxane; and VCAM, vascular cell adhesion molecule.

Concentrations of 8-iso-PGF2{alpha} in the range of 1 nmol/L to 1 µmol/L induce a dose-dependent increase in platelet shape change, calcium release from intracellular stores, and inositol phosphates.17 18 Moreover, 8-iso-PGF2{alpha} causes dose-dependent, irreversible platelet aggregation in the presence of concentrations of collagen, ADP, arachidonic acid, and PGH2/TXA2 analogues that, when acting alone, fail to aggregate platelets.18 Although these effects are prevented by PGH2/TXA2 receptor antagonists and 8-iso-PGF2{alpha} may cross-desensitize biochemical and functional responses to thromboxane mimetics,19 8-iso-PGF2{alpha} fails to activate either of the TX receptor isoforms described in platelets at concentrations that typically circulate during syndromes of oxidant stress.18 The ability of 8-iso-PGF2{alpha} to amplify the aggregation response to subthreshold concentrations of platelet agonists may be relevant to settings where platelet activation and enhanced free-radical formation coincide.18 Similarly, another F2 isoprostane 12-epi-PGF2{alpha}, activates PGF2{alpha} receptors and stimulates proliferative responses in fibroblasts.20 However, whether the local concentrations of isoprostanes achieved in vivo are sufficient to allow them to act as an incidental ligand for prostanoid receptors or whether specific isoprostanes receptors with higher affinity for them might exist remains to be established.


*    Analytical Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 up arrowBiological Effects on Platelets...
 *Analytical Methods
down arrowF2 Isoprostane...
 down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
Both stable-isotope dilution assays using gas chromatography/mass spectrometry (GC/MS) and immunoassays for 8-iso-PGF2{alpha} have been developed.9 21 Although only one metabolite of 8-iso-PGF2{alpha} has been identified to date,22 measurable concentrations of the unmetabolized compound are present in peripheral venous blood, and a relatively reproducible fraction is excreted unchanged in human urine, with no detectable circadian variation. Morrow and Roberts have described GC/MS–based methods for quantifying levels of "total" free F2 isoprostanes in plasma and of F2 isoprostanes esterified to plasma lipids. Moreover, they have identified a tetranor dicarboxylic acid derivative as a potential urinary metabolite of the F2 isoprostanes8 and reported a linear correlation between the estimated urinary excretion of uncharacterized isoprostane metabolites and circulating concentrations of free F2 isoprostanes.21 The development of specific assays for such metabolites may be of particular value as indices of isoprostane generation in plasma rather than as substitutes for specific measurement of F2 isoprostanes in urine. The ex vivo artifactual formation of unmetabolized compounds resulting from auto-oxidation of lipids is much less likely in urine than in plasma. Because 8-iso-PGF2{alpha} represents a major component of the "total" F2 isoprostanes measured in plasma or urine, any cyclooxygenase-dependent formation of this compound in a specific pathophysiological setting may contribute importantly to such an integrated signal, as well as to specific measurements of 8-iso-PGF2{alpha} itself. Given that as many as 64 PGF isomers may theoretically result from free radical–catalyzed transformation of arachidonic acid,5 analysis of distinct isomers with the use of specific internal standards would seem preferable to estimates of "total" isoprostane biosynthesis. Selective analysis of an isomer, distinct from 8-iso PGF2{alpha}, that cannot be formed enzymatically, such as IPF2{alpha}-I, can provide an additional analytical tool to probe the nonenzymatic nature of F2 isoprostane formation in vivo.23

Given that mass spectrometers are confined to relatively specialized laboratories, the application of this methodology to clinical investigation is likely to remain restricted. Both 8-iso-PGF2{alpha} and IPF2{alpha}-1 appear chemically stable in urine frozen at -70°C for as long as 3 months, thus allowing samples to be shipped to a reference laboratory. An alternative approach is to use an immunoassay. Using an antibody that has been described, we have previously published a striking correlation between immunoactive 8-iso-PGF2{alpha} and levels measured by GC/MS.9 However, given that other isomeric species of PGF might be expected to correlate with levels of 8-iso-PGF2{alpha} in these samples and that few have been synthesized to check for cross-reactivity, one cannot state with certainty that 8-iso-PGF2{alpha} immunoreactivity is restricted to 8-iso-PGF2{alpha}. Similarly, no antibodies have been checked for cross-reactivity with isoprostane metabolites, which are largely unidentified. Similar caveats apply to the commercialized reagent for the 8-iso-PGF2{alpha} immunoassay (Cayman Biochemicals, Ann Arbor, Mich). The source of 8-iso-PGF2{alpha} in urine is likely to be conditional on the experimental setting or the disease under study, as is the case with classic PGs.24 However, we assume that urinary excretion of unmetabolized 8-iso-PGF2{alpha} may also reflect oxidant stress in tissues other than the kidney.

No systematic comparisons have been reported of F2 isoprostane measurements with other indices of oxidant stress. However, it should be emphasized that the latter suffer from major limitations in assessing the actual rate of lipid peroxidation in vivo. This has been measured by various methods, including the analysis of lipid hydroperoxides, conjugated dienes, reactive aldehydes, and estimation of expired hydrocarbons (reviewed in Reference 2525 ). A widely used index of peroxidation is the measurement of malondialdehyde (MDA) by the thiobarbituric acid assay. However, due to the uncertainty in the structure of the derivative and the lack of specificity of the assay, the level of MDA is usually expressed as TBARS. Development of a GC/MS assay for MDA has recently demonstrated that the commonly used thiobarbituric acid assay for MDA overestimates actual MDA levels by >10-fold, possibly resulting from cross-reactivity with other aldehydes and the harsh conditions used in sample preparation.26 Moreover, MDA is a byproduct of cyclooxygenase activity in platelets,27 and persistent platelet activation in vivo is a common feature of many clinical syndromes associated with enhanced lipid peroxidation (see below). Similarly, the accuracy of exhaled pentane as an index of in vivo lipid peroxidation has been questioned.28

Lipoprotein oxidation is unlikely to occur in plasma because of the presence of high concentrations of antioxidants and proteins that chelate metal ions.29 It is more likely to occur in a microenvironment where antioxidants can become depleted and lipoproteins are exposed to oxidative stress. Because of the substantial uncertainly as to the most likely biochemical pathways involved in LDL oxidation within the artery wall,29 it is unclear whether the wide variations reported in the susceptibility of LDL from different individuals to oxidation ex vivo have any relevance to the extent of LDL oxidation in vivo.


*    F2 Isoprostane Formation in Human Vascular Disease
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 up arrowBiological Effects on Platelets...
 up arrowAnalytical Methods
 *F2 Isoprostane...
down arrowEffects of Antioxidants
 down arrowConclusions
 down arrowReferences
 
A limited number of studies have been completed during the past 2 years addressing the formation of F2 isoprostanes in clinical settings putatively associated with oxidative damage, either as a result of acute ischemia/reperfusion or long-standing metabolic abnormalities. Free radicals are thought to mediate the reperfusion injury that characterizes thrombolytic therapy after myocardial infarction.30 31 32 The myocardial stunning described in animal models of coronary occlusion/reperfusion33 34 35 and in some patients undergoing thrombolytic therapy36 37 is considered to be a manifestation of this phenomenon. Delanty et al38 have recently reported that urinary 8-iso-PGF2{alpha} excretion was unchanged following thrombotic circumflex artery occlusion in a canine model of coronary thrombolysis but increased significantly immediately following reperfusion with thrombolytic drugs. Moreover, urinary 8-iso-PGF2{alpha} was increased in patients with acute myocardial infarction given thrombolytic therapy (mostly streptokinase) when compared with both age-matched, healthy control subjects and patients with stable coronary heart disease.38 The global myocardial reperfusion injury that may follow coronary artery bypass grafting (CABG) is also thought to result from free-radical generation in the reperfused vasculature.39 40 In the study of Delanty et al,38 urinary excretion of 8-iso-PGF2{alpha} increased following elective CABG and peaked 15 minutes after global myocardial reperfusion. The increase in urinary 8-iso-PGF2{alpha} during coronary reperfusion corresponded both in time and magnitude to changes in spin-trapping of {alpha}-phenyl-N-butylnitrone adducts, as detected by electron paramagnetic resonance in two patients.38 Interestingly, increased levels of urinary 8-iso-PGF2{alpha} have also been detected following carotid reperfusion in patients undergoing endarterectomy (D. Praticò et al, 1997, unpublished results) and in patients undergoing coronary angioplasty.41 The functional consequences of enhanced formation of this biologically active eicosanoid have not yet been explored. However, these recent findings provide a rationale for dose-finding studies of natural or synthetic antioxidants using urinary 8-iso-PGF2{alpha} as a biochemical end point. Enhanced formation of 8-iso-PGF2{alpha} might be expected in patients with acute ischemic stroke, a condition in which formation of free radicals is likely to occur. However, in a recent study of 62 patients with acute ischemic stroke from whom at least two consecutive 6-hour urine samples were obtained during the first 72 hours after the onset of symptoms, no consistent changes in immunoreactive 8-iso-PGF2{alpha} excretion were detected, in contrast with the isosodic increases in TX metabolite excretion.42 Increased oxidant stress might occur as an early, transient event that could be largely missed by the timing of urine sampling, or the signal-to-noise ratio might be too small to be detected at a distance from its source. These negative findings are useful, however, in demonstrating that in a clinical condition where platelets are clearly activated in an episodic fashion,43 there are no apparently concurrent changes in 8-iso-PGF2{alpha} formation and excretion, thus implying trivial if any contribution from platelet cyclooxygenase activity.

Persistently enhanced formation of F2 isoprostanes has been reported in association with several cardiovascular risk factors, including cigarette smoking,21 44 diabetes mellitus,45 46 47 and hypercholesterolemia,48 49 conditions putatively characterized by increased lipid peroxidation in response to the various constituents of cigarette smoke or complex metabolic abnormalities. Accelerated LDL oxidation,29 as well as platelet activation,50 are common features of these conditions. In chronic cigarette smokers, both plasma levels of F2 isoprostanes and urinary excretion of 8-iso-PGF2{alpha} are increased in comparison with sex- and age-matched nonsmokers.21 44 Moreover, there is a relationship between the number of cigarettes smoked and excreted 8-iso-PGF2{alpha} levels.44 Smoking had no short-term effects on circulating levels of F2 isoprostanes.21 However, the levels of free and esterified F2 isoprostanes in plasma21 and of 8-iso-PGF2{alpha} in urine44 fell significantly after cessation of smoking. Low-dose aspirin (75 mg/d for 10 days) failed to suppress urinary 8-iso-PGF2{alpha} excretion despite suppression of platelet cyclooxygenase-1 activity and TX metabolite excretion.44

Although diabetes mellitus is a clearly established risk factor for cardiovascular disease, the mechanism(s) responsible for accelerated atherogenesis remain elusive. Altered lipoprotein levels; changes in lipoprotein composition, possibly affecting LDL binding to its receptors; and reduced LDL clearance resulting from impaired receptor recognition of glycated LDL have been described in diabetic patients (reviewed in Reference 5151 ). Moreover, both high glucose levels and protein glycation enhance LDL oxidation by metal ions, and these reactions also yield advanced glycosylation end (AGE) products.29 51 In fact, LDLs isolated from non–insulin-dependent diabetics (NIDDM) contain higher levels of AGE products and conjugated dienes and are more easily oxidized by copper than is native LDL.52 In addition, plasma from patients whose insulin-dependent diabetes mellitus (IDDM) is poorly controlled has less antioxidant capacity.53 Consistent with the concept of enhanced lipid peroxidation in diabetes, Gopaul et al45 have reported that the average concentration of esterified 8-iso-PGF2{alpha} in plasma from 39 patients with NIDDM was approximately threefold higher than in healthy individuals. However, increased plasma levels of 8-iso-PGF2{alpha} were not functions of hyperglycemia or hyperlipidemia.45 Catella-Lawson et al46 have recently reported a trend toward increased urinary 8-iso-PGF2{alpha} excretion in a group of 18 diabetics, with statistically significant elevations in patients presenting with diabetic ketoacidosis. Furthermore, increased oxidizability of LDL in diabetics was more readily reflected by 8-iso-PGF2{alpha} than by conjugated diene formation.46 In the study of Ciabattoni et al,47 urinary immunoreactive 8-iso-PGF2{alpha} was significantly higher in a group of 55 NIDDM and 23 IDDM patients than in age-matched control subjects by approximately twofold. Tight metabolic control was associated with a statistically significant reduction in 8-iso-PGF2 excretion, by {approx}40%.47

High cholesterol levels have an established role in the development of atherosclerotic vascular lesions and in cardiovascular events induced by vascular occlusion.54 Evidence for this role has been inferred from both epidemiological and interventional studies.55 56 However, occlusive events may occur in the absence of grossly elevated cholesterol levels, particularly in the presence of other risk factors, such as cigarette smoking, diabetes mellitus, and hypertension. A link between moderately elevated cholesterol levels and other risk factors for cardiovascular disease has been proposed to involve oxidative modifications of LDL, although direct evidence of its functional importance in human atherogenesis remains to be provided.2 Oxidatively modified LDL has been found in foam cells and atherosclerotic plaques and has been shown to acquire a variety of properties possibly relevant to the process of atherogenesis.2 3 Moreover, increased susceptibility of LDL to in vitro oxidation has been demonstrated in hypercholesterolemic patients.57 58

Type IIa hypercholesterolemia is also characterized by platelet activation in vivo, as reflected by enhanced TX metabolite excretion.59 Immunoreactive 8-iso-PGF2{alpha} is altered in patients with hypercholesterolemia and appears to contribute to platelet activation in this setting.48 Paired measurements of 8-iso-PGF2{alpha} and 11-dehydro-TXB2 in 40 hypercholesterolemic patients and 40 age- and sex-matched control subjects revealed a highly significant linear correlation between the two. Urinary 8-iso-PGF2{alpha} was significantly higher in hypercholesterolemic patients than in control subjects by twofold to threefold, and its rate of excretion was directly correlated with LDL cholesterol levels and inversely related to the vitamin E content of LDL. Urinary immunoreactive 8-iso-PGF2{alpha} was unchanged following a 2-week dosing with aspirin or indobufen, a reversible cyclooxygenase inhibitor, despite complete suppression of TX metabolite excretion. Consistent with the hypothesis of enhanced 8-iso-PGF2{alpha} formation's contribution to platelet activation in this setting, dose-dependent suppression of the former by vitamin E supplementation was associated with comparable reductions in 11-dehydro-TXB2 excretion.48 Thus, enhanced nonenzymatic peroxidation of arachidonic acid may provide a biochemical link between oxidant stress and platelet activation in the setting of hypercholesterolemia. Using MS, Reilly et al49 demonstrated that both urinary IPF2{alpha}-I and 8-iso-PGF2{alpha} levels were elevated in patients with homozygous and heterozygous familial hypercholesterolemia. Excretion of the two isoprostanes was highly correlated within both groups of hyperlipidemic patients. Interestingly, levels of 8-iso-PGF2{alpha} esterified in circulating LDL correlated with urinary levels of this isoprostane in patients with familial homozygous hypercholesterolemia.

The studies of 8-iso-PGF2{alpha} formation conducted so far appear to exclude a significant contribution from a cyclooxygenase-dependent mechanism of biosynthesis in vivo. This is supported by 1) dissociation of 8-iso-PGF2{alpha} and 11-dehydro-TXB2 excretion in acute ischemic stroke; 2) no effects of aspirin and other nonspecific cyclooxygenase inhibitors on urinary 8-iso-PGF2{alpha} in healthy subjects, acute stroke patients, and hypercholesterolemic subjects; and 3) correlation between urinary 8-iso-PGF2{alpha} and IPF2{alpha}-I in the settings of percutaneous transluminal coronary angioplasty and hypercholesterolemia, as well as between levels of both isoprostanes in atherosclerotic plaque. The availability of selective inhibitors of PGH synthase-2 will permit further definition of the potential contribution of this pathway to formation of 8-iso-PGF2{alpha}, particularly in the setting of inflammation or increased cellular proliferation, where induction of this enzyme might be anticipated.


*    Effects of Antioxidants
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 up arrowBiological Effects on Platelets...
 up arrowAnalytical Methods
 up arrowF2 Isoprostane...
 *Effects of Antioxidants
down arrowConclusions
 down arrowReferences
 
Numerous epidemiological studies have shown that dietary intake of vitamin E is inversely associated with the risk of cardiovascular disease, though few randomized intervention trials have prospectively tested the cardiovascular benefit from vitamin treatment.60 In general, the epidemiological studies have been interpreted to suggest that prevention of cardiovascular disease requires large amounts of vitamin E, in excess of the conventional dietary intake. However, there is substantial uncertainty as to the optimal dose of vitamin E supplementation, largely because of inadequate biochemical end points for its efficacy. This is reflected in a wide range of doses tested in randomized clinical trials, from as low as 50 mg daily of racemic {alpha}-tocopherol to as high as {approx}500 mg daily.60 61 A number of mechanisms have been suggested to contribute to the putative beneficial effects of vitamin E, including inhibition of LDL oxidation and prevention of fatty streak formation (reviewed in Reference 2929 ), stabilization of coronary lesions,61 a direct antiplatelet effect,62 or improvement of endothelium-dependent vasodilation.63

Limited information is available on the effects of vitamin E on F2 isoprostane formation. Thus, Reilly et al44 have reported no significant changes in urinary 8-iso-PGF2{alpha} excretion following a 5-day course of vitamin E supplementation in a limited number of moderate (100 U/d) or heavy (800 U/d) smokers. In contrast, vitamin C (2 g/d) alone or in combination with vitamin E significantly depressed urinary 8-iso-PGF2{alpha} in heavy smokers to a comparable level achieved by smoking cessation.44 Two-week dosing with vitamin E (100 to 600 mg daily) was found to reduce immunoreactive 8-iso-PGF2{alpha} excretion in a dose-dependent fashion in hypercholesterolemic subjects, with all measurements falling within the range of healthy subjects at 600 mg daily.48 Similar changes in urinary immunoreactive 8-iso-PGF2{alpha} have been reported following high-dose vitamin E supplementation in NIDDM patients.47 Clearly, controlled studies are needed to assess the dose-response relationship and the time dependence of the effects of antioxidant vitamins on F2 isoprostane formation. However, the results of the available studies do provide a rationale for dose-ranging studies based on measurements of urinary 8-iso-PGF2{alpha} in appropriate target populations. This may help resolve some of the uncertainty about the optimal dose of vitamin E supplementation in various clinical settings and provide a more rational basis for disease selection for large-scale interventional trials.


*    Conclusions
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 up arrowBiological Effects on Platelets...
 up arrowAnalytical Methods
 up arrowF2 Isoprostane...
 up arrowEffects of Antioxidants
 *Conclusions
down arrowReferences
 
Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation in vivo. Besides the F2 isoprostanes extensively discussed in this review, isomers of other PGs and leukotrienes have also been recently described.64 65 Enhanced urinary excretion of 8-iso-PGF2{alpha} has been characterized in association with cardiac reperfusion injury and cardiovascular risk factors, including cigarette smoking, diabetes mellitus, and hypercholesterolemia. Besides providing a reliable, noninvasive index of lipid peroxidation in these settings, measurements of specific F2 isoprostanes, such as IPF2{alpha}-I and 8-iso-PGF2{alpha}, in urine may provide sensitive biochemical end points for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF2{alpha} in vitro suggest that it and other isoeicosanoids64 65 may modulate the functional consequences of lipid peroxidation, evidence that this is likely in vivo remains inadequate at this time. However, the analytical and pharmacological tools are now available to explore this hypothesis, as outlined in this review.


*    Acknowledgments
 
This work was supported by grants from the National Institutes of Health, Bethesda, Md (1P50HL54500 and MO1 RR 00040 to G.A.F.), from the Wellcome Trust (to G.A.F.), Bayer AG (to C.P.), and a BIOMED grant from the European Union (BMHI-CT93-1533 to C.P.). Dr FitzGerald is the Robinette Foundation Professor of Cardiovascular Medicine. The expert editorial assistance of Gail Vogel and Susan Weber is gratefully acknowledged.

Received February 18, 1997; accepted April 29, 1997.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMechanisms of Formation
 up arrowBiological Effects on Platelets...
 up arrowAnalytical Methods
 up arrowF2 Isoprostane...
 up arrowEffects of Antioxidants
 up arrowConclusions
 *References
 

  1. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842.[Abstract/Free Full Text]
  2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.[Medline] [Order article via Infotrieve]
  3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
  4. O'Connor DE, Mihelic ED, Coleman MC. Stereochemical course of the auto-oxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclo endoperoxides. J Am Chem Soc. 1984;106:3577-3584.
  5. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-9387.[Abstract/Free Full Text]
  6. Lynch SM, Morrow JD, Roberts LJ II, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93:998-1004.
  7. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157-33160.[Free Full Text]
  8. Awad JA, Morrow JD, Takahashi K, Roberts LJ II. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem. 1993;268:4161-4169.[Abstract/Free Full Text]
  9. Wang Z, Ciabattoni G, Creminon C, Lawson J, FitzGerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2{alpha} excretion in man. J Pharmacol Exp Ther. 1995;275:94-100.[Abstract/Free Full Text]
  10. Pratico D, FitzGerald GA. Generation of 8-epi prostaglandin F2{alpha} by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271:8919-8924.[Abstract/Free Full Text]
  11. Pratico D, Iuliano L, Spagnoli L, Mauriello A, Lawson JA, Rokach J, Maclouf J, Violi F, FitzGerald GA. Localization of distinct E2 isoprostanes in human atherosclerotic lesions. J Clin Invest.. 1997;100:2028-2034.[Medline] [Order article via Infotrieve]
  12. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2{alpha}. J Biol Chem. 1995;270:9800-9808.[Abstract/Free Full Text]
  13. Patrignani P, Santini G, Panara MR, Sciulli G, Greco A, Rotondo MT, Di Giamberardino M, Maclouf J, Ciabattoni G, Patrono C. Induction of prostaglandin endoperoxide synthase-2 in human monocytes is associated with cyclooxygenase-dependent F2-isoprostane formation. Br J Pharmacol. 1996;118:1285-1293.[Medline] [Order article via Infotrieve]
  14. Panara MR, Greco A, Santini G, Sciulli G, Rotondo MT, Padovano R, Di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C, Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphon amido-6-(2,4-difluorothiophenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol. 1995;116:2429-2434.[Medline] [Order article via Infotrieve]
  15. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJ II, Hoover RL, Badr KF. Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2{alpha}, in the rat: evidence for interaction with thromboxane A2 receptors. J Clin Invest. 1992;90:136-141.
  16. Fukunaga M, Makita N, Roberts LJ II, Morrow JD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993;264:C1619–1624.[Abstract/Free Full Text]
  17. Morrow JD, Minton TA, Roberts LJ II. The F2-isoprostane, 8-epi-prostaglandin F2{alpha}, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 1992;44:155-163.[Medline] [Order article via Infotrieve]
  18. Praticò D, Smyth EM, Violi F, FitzGerald GA Local amplification of platelet function by 8-epi prostaglandin F2{alpha} is not mediated by thromboxane receptor isoforms. J Biol Chem. 1996;271:14916-14924.[Abstract/Free Full Text]
  19. Kinsella BT, O'Mahony DJ, FitzGerald GA. The human thromboxane A2 receptor {alpha} isoform (TP{alpha}) functionally couples to the G-proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2{alpha}. J Pharmacol Exp Ther. In press.
  20. Kunapuli P, Lawson JA, Rokach JA, FitzGerald GA. Functional characterization of the ocular PGF2{alpha} receptor: activation by the isoprostane 12-epi-PGF2{alpha}. J Biol Chem.. 1997;272:27147-27154.[Abstract/Free Full Text]
  21. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ II. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.[Abstract/Free Full Text]
  22. Roberts LJ II, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane, 8-iso-prostaglandin F2{alpha} in humans. J Biol Chem. 1996;271:20617-20620.[Abstract/Free Full Text]
  23. Adiyaman M, Lawson JA, Hwang S-W, Khanapure SP, FitzGerald GA, Rokach J. Total synthesis of a novel isoprostane IPF2{alpha}-I and its identification in biological fluids. Tetrahedron Lett. 1996;37:4849-4852.
  24. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane A2 biosynthesis in cardiovascular disease. Circulation. 1983;67:1174-1177.[Free Full Text]
  25. Gutteridge JMC, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci. 1990;15:129-135.[Medline] [Order article via Infotrieve]
  26. Yeo HC, Helbock HJ, Chyu DW, Ames BN. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem. 1994;220:391-396.[Medline] [Order article via Infotrieve]
  27. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2294-2298.[Abstract/Free Full Text]
  28. Cailleux A. Allain P. Is pentane a normal constituent of human breath? Free Radic Res Commun. 1993;18:323-327.[Medline] [Order article via Infotrieve]
  29. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707-727.[Medline] [Order article via Infotrieve]
  30. Davies SW, Ranjadayalan K, Wickens DG, Dormandy TL, Timmis AD. Lipid peroxidation associated with successful thrombolysis. Lancet. 1990;335:741-743.[Medline] [Order article via Infotrieve]
  31. Purvis J, Young L, Lightbody J, Trimble E, Adgey J. Free radical production following thrombolytic therapy in acute myocardial infarction. Circulation. 1992;86(suppl I):I-804. Abstract.
  32. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia/reperfusion: resolved and unresolved issues. Circulation. 1989;80:1115-1127.[Abstract/Free Full Text]
  33. Gross GJ, Farber NE, Hardman HF, Warltier DC. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol. 1986;250:H372–H377.
  34. Bolli R, Jeroudi MO, Patel BS, Aruoma OI, Halliwell B, Lai EK, McCay PB. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res. 1989;65:607-622.[Abstract/Free Full Text]
  35. Bolli R, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap, {alpha}-phenyl N-tert-butyl nitrone. J Clin Invest. 1988;82:476-485.
  36. Davies SW, Ranjadayalan K, Wickens DG, Dormandy TL, Umachandran V, Timmis AD. Free radical activity and left ventricular function after thrombolysis for acute infarction. Br Heart J. 1993;69:114-120.[Abstract/Free Full Text]
  37. Bolli R. Myocardial `stunning' in man. Circulation. 1992;86:1671-1691.[Free Full Text]
  38. Delanty N, Reilly M, Pratico D, Lawson JA, McCarthy JF, Wood AE, Ohnishi ST, Fitzgerald DJ, FitzGerald GA. 8-epi PGF2{alpha} generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation. 1997;96:2492-2499.
  39. Ferreira R, Llesuy S, Milei J, Scordo D, Hourquebie H, Molteni L, dePalma C, Boveris A. Assessment of myocardial oxidative stress in patients after myocardial revascularization. Am Heart J. 1988;115:307-312.[Medline] [Order article via Infotrieve]
  40. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J, Armitage JM, Hardesty RL. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J Am Coll Cardiol. 1990;15:1261-1269.[Abstract]
  41. Reilly MP, Delanty N, O'Callaghan P, Crean P, Roy L, FitzGerald GA. Increased generation of the F2 isoprostanes, IPF2{alpha}-1 and 8-iso-PGF2{alpha} in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. In press.
  42. Ciabattoni G, Patrono C, Van Kooten F, Koudstaal PJ. Dissociation of platelet activation and lipid peroxidation in acute ischemic stroke. J Invest Med. 1995;43:292A. Abstract.
  43. Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, Van Gijn J, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke. Stroke. 1994;25:278-281.[Abstract]
  44. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996;94:19-25.[Abstract/Free Full Text]
  45. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2{alpha} levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 1995;368:225-229.[Medline] [Order article via Infotrieve]
  46. Catella-Lawson F, Kapoor S, Pratico D, Braunstein SN, Caraballo V, FitzGerald GA. Oxidative stress and diabetes mellitus. J Invest Med. 1996;44:223A. Abstract.
  47. Ciabattoni G, Consoli A, Vitacolonna E, Mezzetti A, Santarone S, Pennese E, Falco A, Davi G, Patrono C. In vivo formation of 8-epi-prostaglandin F2{alpha} in diabetes mellitus: effects of tight metabolic control and vitamin E supplementation. Thromb Haemost. In press. Abstract.
  48. Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Constantini F, Cipallone F, Bittolo Bon G, Ciabattoni G, Patrono C. In vivo formation of 8-epi-PGF2{alpha} is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. In press.
  49. Reilly MP, Delanty N, Tremoli E, Rader D, FitzGerald GA. Elevated levels of 8-epi prostaglandin F2{alpha}, in familial hypercholesterolemia: evidence of oxidative stress in vivo. Circulation. 1996;94(suppl I):I-638. Abstract.
  50. Patrono C, Davi G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med. 1992;2:15-20.
  51. Palinski W, Witztum JL. Oxidative stress and diabetes mellitus. In: Schwartz CJ, Born GVR, eds. New Horizons in Diabetes Mellitus and Cardiovascular Disease. Rapid Science Publishers; 1996:81-93.
  52. Chisolm GM, Irwin KC, Penn MS. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes. 1992;4:61-66.
  53. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 1994;43:1010-1014.[Abstract]
  54. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: mew insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.[Abstract/Free Full Text]
  55. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study:(4S). Lancet. 1994;344:1383-1389.[Medline] [Order article via Infotrieve]
  56. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.[Abstract/Free Full Text]
  57. Lavy A, Brook GJ, Dankner G, Amotz AM, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism. 1991;40:794-799.[Medline] [Order article via Infotrieve]
  58. Cominacini L, Pastorino AM, Garbin U, Campagnola M, De Santis A, Davoli A, Faccini G, Bertozzo L, Pasini F, Pasini AF. The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition. 1994;10:527-531.[Medline] [Order article via Infotrieve]
  59. Davi G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992:85:1792-1798.
  60. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. Ann Intern Med. 1995;123:860-872.[Abstract/Free Full Text]
  61. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.[Medline] [Order article via Infotrieve]
  62. Freedman JE, Farhat JH, Loscalzo J, Keaney JF. {alpha}-Tocopherol inhibits aggregation of human platelets by a protein kinase C–dependent mechanism. Circulation. 1996;94:2434-2440.[Abstract/Free Full Text]
  63. Riemersma RA. Coronary heart disease and vitamin E. Lancet. 1996;347:776-777.[Medline] [Order article via Infotrieve]
  64. Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC, Badr KF, Robert LJ II. Free radical-induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994;269:4317-4326.[Abstract/Free Full Text]
  65. Harrison KA, Murphy RC. Isoleukotrienes: biologically active free radical products of lipid peroxidation. J Biol Chem. 1995;269:17273-17278.



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
S. Cottone, G. Mule, M. Guarneri, A. Palermo, M. C. Lorito, R. Riccobene, R. Arsena, F. Vaccaro, A. Vadala, E. Nardi, et al.
Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients
Nephrol. Dial. Transplant., September 4, 2008; (2008) gfn489v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. Y. Kim, Y. J. Hyun, Y. Jang, B. K. Lee, J. S. Chae, S. E. Kim, H. Y. Yeo, T.-S. Jeong, D. W. Jeon, and J. H. Lee
Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study
Am. J. Clinical Nutrition, September 1, 2008; 88(3): 630 - 637.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
F. Martino, L. Loffredo, R. Carnevale, V. Sanguigni, E. Martino, E. Catasca, C. Zanoni, P. Pignatelli, and F. Violi
Oxidative Stress Is Associated With Arterial Dysfunction and Enhanced Intima-Media Thickness in Children With Hypercholesterolemia: The Potential Role of Nicotinamide-Adenine Dinucleotide Phosphate Oxidase
Pediatrics, September 1, 2008; 122(3): e648 - e655.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. Ky, A. Burke, S. Tsimikas, M. L. Wolfe, M. G. Tadesse, P. O. Szapary, J. L. Witztum, G. A. FitzGerald, and D. J. Rader
The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans
J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1653 - 1662.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. Raff, T. Tholstrup, S. Basu, P. Nonboe, M. T. Sorensen, and E. M. Straarup
A Diet Rich in Conjugated Linoleic Acid and Butter Increases Lipid Peroxidation but Does Not Affect Atherosclerotic, Inflammatory, or Diabetic Risk Markers in Healthy Young Men
J. Nutr., March 1, 2008; 138(3): 509 - 514.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Atteritano, H. Marini, L. Minutoli, F. Polito, A. Bitto, D. Altavilla, S. Mazzaferro, R. D'Anna, M. L. Cannata, A. Gaudio, et al.
Effects of the Phytoestrogen Genistein on Some Predictors of Cardiovascular Risk in Osteopenic, Postmenopausal Women: A Two-Year Randomized, Double-Blind, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3068 - 3075.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Faraday, L. R. Yanek, R. Mathias, J. E. Herrera-Galeano, D. Vaidya, T. F. Moy, M. D. Fallin, A. F. Wilson, P. F. Bray, L. C. Becker, et al.
Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1
Circulation, May 15, 2007; 115(19): 2490 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C.-C. Lin, C.-F. Chang, M.-Y. Lai, T.-W. Chen, P.-C. Lee, and W.-C. Yang